Immunome Appoints Andrew Badley, M.D., to COVID-19 Advisory Board – Business Wire

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today announced the appointment of Andrew D. Badley, M.D., to the companys COVID-19 Advisory Board. Dr. Badley currently serves as the Chair of the Mayo COVID-19 Research Taskforce and is a leading voice in the fight against COVID-19.

Dr. Badley is a thought leader in infectious disease, and specifically COVID-19. I am delighted to announce his appointment to Immunomes COVID-19 Advisory Board, said Purnanand Sarma, Ph.D., President and CEO of Immunome. Andrews experience will be invaluable as we develop novel therapeutics to combat the evolving COVID-19 virus and other novel outbreaks.

Dr. Badley is a well-known physician and researcher who focuses on virus-host interactions, particularly on how viral proteins modify the host-immune response and on cell survival. Dr. Badley has spent 19 years with the Mayo Clinic in various roles. Currently, Dr. Badley is a Professor of Infectious Disease, serves as the Chair of the Mayo Clinic COVID-19 Research Taskforce, and is Professor and Chair of the Department of Molecular Medicine. Dr. Badley began his career at the University of Ottawa, where he served as an Associate Professor and Infectious Disease Physician. Dr. Badley received his bachelors and medical degrees from Dalhousie University. After Dalhousie, Dr. Badley completed his residency in internal medicine and his fellowship in infectious disease at Mayo School of Graduate Medical Education.

About Immunome

Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The companys initial focus is on developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunomes proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease. For more information, please visit http://www.immunome.com.

Forward-Looking Statements

This press release includes certain disclosures that contain forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding Immunomes beliefs and expectations regarding the advancement of its oncology and COVID-19 therapeutic antibody programs, execution of its clinical and strategic plans, anticipated upcoming milestones for IMM-BCP-01 and IMMONC01, including expectations regarding therapeutic potential and benefits thereof, and IND filings. Forward-looking statements may be identified by the words anticipate, believe, estimate, expect, intend, plan, project, may, will, could, should, seek, potential and similar expressions. Forward-looking statements are based on Immunomes current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on Immunomes business, operations, strategy, goals and anticipated milestones; Immunomes ability to execute on its strategy including with respect to the timing of its R&D efforts, IND filings, initiation of clinical studies and other anticipated milestones; the timing and effectiveness of any antibody therapeutics which may be developed by Immunome; Immunomes ability to fund operations; and the additional risks and uncertainties set forth more fully under the caption Risk Factors in Immunomes Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 25, 2021, and elsewhere in Immunomes filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Immunome undertakes no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.

Go here to read the rest:
Immunome Appoints Andrew Badley, M.D., to COVID-19 Advisory Board - Business Wire